featured
Lurbinectedin in Patients With Pretreated Germline BRCA1/2 Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
ESMO Open 2022 Aug 26;7(5)100571, V Boni, B Pistilli, I Braña, GI Shapiro, J Trigo, V Moreno, D Castellano, C Fernández, C Kahatt, V Alfaro, M Siguero, A Zeaiter, F Longo, K Zaman, A Antón, A Paredes, G Huidobro, V SubbiahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.